Abstract

Infection of the novel coronavirus SARS-CoV-2 can be blocked by a human monoclonal antibody

Vaccines and targeted therapeutics for treatment of the respiratory disease COVID-19, caused by the coronavirus SARS-CoV-2, are currently lacking. Based on the results of this study, it was reported for the first time that a human monoclonal antibody, 47D11, can neutralize SARS-CoV-2 in cell culture. This cross-neutralizing antibody targets a communal epitope on the virus via a mechanism that is independent of receptor-binding inhibition. It will be useful for development of antigen detection tests and serological assays targeting SARS-CoV-2. Neutralizing antibodies can alter the course of infection in the infected host supporting virus clearance or protect an uninfected host that is exposed to the virus. Hence, this antibody may offer potential for prevention and/or treatment of COVID-19. The antibody binding to cell surface spike proteins of SARS-CoV-2 was measured by immunofluoresence microscopy using a confocal microscope from Leica Microsystems. Refer to the publication for more details.

Topics & Tags

Read the full article:

C. Wang, W. Li, D. Drabek, N.M.A. Okba, R. van Haperen, A.D.M.E. Osterhaus, F.J.M. van Kuppeveld, B.L. Haagmans, F. Grosveld, B.-J. Bosch:

A human monoclonal antibody blocking SARS-CoV-2 infection

Nat. Commun. (2020) vol. 11, art. num. 2251, DOI: 10.1038/s41467-020-16256-y

Interested to know more?

Talk to our experts. We are happy to answer all your questions and concerns.

Contact Us

Do you prefer personal consulting?

  • Leica Microsystems Inc.
    1700 Leider Lane
    Buffalo Grove, IL 60089 United States
    Office Phone : +1 800 248 0123
    Service Phone : 1 800 248 0223
    Fax : +1 847-236-3009

You will find a more detailed list of local contacts here.